摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-(3,5-dimethyl-1H-pyrazol-1-yl)pyrimidin-4-amine | 1447965-78-7

中文名称
——
中文别名
——
英文名称
6-(3,5-dimethyl-1H-pyrazol-1-yl)pyrimidin-4-amine
英文别名
6-(3,5-dimethylpyrazol-1-yl)pyrimidin-4-amine
6-(3,5-dimethyl-1H-pyrazol-1-yl)pyrimidin-4-amine化学式
CAS
1447965-78-7
化学式
C9H11N5
mdl
——
分子量
189.22
InChiKey
SRJMNPWZWJBMPL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1
  • 重原子数:
    14
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.22
  • 拓扑面积:
    69.6
  • 氢给体数:
    1
  • 氢受体数:
    4

文献信息

  • Substituted 6-(1H-pyrazol-1-yl)pyrimidin-4-amine derivatives and uses thereof
    申请人:Bayer Aktiengesellschaft
    公开号:US11208400B2
    公开(公告)日:2021-12-28
    The present invention covers substituted 6-(1H-pyrazol-1-yl)pyrimidin-4-amine compounds of general formula (I) as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular and renal diseases, as a sole agent or in combination with other active ingredients.
    本发明涉及本文所述和定义的通式(I)的取代 6-(1H-吡唑-1-基)嘧啶-4-胺化合物、制备所述化合物的方法、用于制备所述化合物的中间体化合物、包含所述化合物的药物组合物和组合物,以及使用所述化合物制造治疗或预防疾病,特别是治疗和/或预防心血管疾病和肾脏疾病的药物组合物,作为单独制剂或与其他活性成分组合使用。
  • SUBSTITUTED 6-(1H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE DERIVATIVES AND USES THEREOF
    申请人:Bayer Aktiengesellschaft
    公开号:US20200055842A1
    公开(公告)日:2020-02-20
    The present invention covers substituted 6-(1H-pyrazol-1-yl)pyrimidin-4-amine compounds of general formula (I) as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular and renal diseases, as a sole agent or in combination with other active ingredients.
查看更多